|Aslan Pharmaceuticals Pte Ltd., of Singapore||Varlitinib||EGFR and HER2/neu inhibitor||Biliary tract cancer||Phase I/II study in advanced or metastatic biliary tract cancer in patients who have not received systemic therapy for advanced/metastatic disease terminated; sponsor decided not to proceed to phase II|
|Nanoform Finland plc, of Helsinki, Finland||Piroxicam||Nanoparticle version of nonsteroidal anti-inflammatory drug||Undisclosed||Interim results suggest that 20-mg nanoformed oral tablet achieved significantly faster absorption when compared to 20-mg reference oral piroxicam tablet (Felden); time of maximum plasma concentration was obtained earlier than with reference product; final results of study are expected before the end of the second quarter of 2021|
|Birchbiomed Inc., of Vancouver, British Columbia||FS2 cream||Inhibits formation of collagen||Keloid scars||Reported statistically significant results showed improvement in Vancouver Scar Scale vs. Mederma (p<0.001) and vs. vehicle (p<0.05) at the conclusion of the 180-day trial|
|Immutep Ltd., of Sydney||GSK-2831781||CD223 modulator||Ulcerative colitis||Partner Glaxosmithkline discontinued trial based on assessment of interim analysis, in consultation with data review committee|
|Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., and Sanofi SA, of Paris||Cemiplimab||Anti-PD-1 antibody||Classical Hodgkin lymphoma||Study testing combination with radiotherapy in early stage disease withdrawn due to business decision|
|Senhwa Biosciences Inc., of Taipei, Taiwan, and San Diego||Silmitasertib||Small molecule targeting CK2||COVID-19||First patient enrolled in investigator-initiated trial in hospitalized patients|
|Windtree Therapeutics Inc., of Warrington, Pa.||Lucinactant||Aerosolized KL4 surfactant therapy||Respiratory distress syndrome||Trial testing inhalation formulation in preterm neonates suspended due to business reasons|
For more information about individual companies and/or products, see Cortellis.